

Circular RNA circSmoc1-2 regulates vascular calcification by acting as a miR-874-3p sponge in vascular smooth muscle cells

Juhee Ryu,^{1,2,3,4,5,6} Nakwon Choe,^{3,5} Duk-Hwa Kwon,^{2,3,5} Sera Shin,^{3,5} Yeong-Hwan Lim,^{3,6} Gwangho Yoon,^{2,6} Ji Hye Kim,⁷ Hyung Seok Kim,⁸ In-Kyu Lee,⁹ Youngkeun Ahn,^{3,10} Woo Jin Park,^{3,11} Hyun Kook,^{3,5} and Young-Kook Kim^{3,6}

¹Chonnam University Research Institute of Medical Sciences, Jeollanam-do, Republic of Korea; ²The BK21 FOUR Center for Global Future Biomedical Scientists at Chonnam National University Medical School, Jeollanam-do, Republic of Korea; ³Basic Research Laboratory for Vascular Remodeling, Chonnam National University Medical School, Jeollanam-do, Republic of Korea; ⁴College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Republic of Korea; ⁵Department of Pharmacology, Chonnam National University Medical School, Jeollanam-do, Republic of Korea; ⁶Department of Biochemistry, Chonnam National University Medical School, Jeollanam-do, Republic of Korea; ⁷Chonnam National University Hwasun Hospital Biomedical Research Institute, Jeollanam-do, Republic of Korea; ⁸Department of Forensic Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea; ⁹Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea; ¹⁰Department of Cardiology, Cardiovascular Center, Chonnam National University Hospital, Gwangju, Republic of Korea; ¹¹College of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, Republic of Korea

Vascular calcification (VC), or calcium deposition inside the blood vessels, is common in patients with atherosclerosis, cardiovascular disease, and chronic kidney disease. Although several treatments are available to reduce calcification, the incidence of VC continues to rise. Recently, there have been several reports describing the regulation of circular RNAs (circRNAs) in various diseases. However, the role of circRNAs in VC has not yet been fully explored. Here, we investigated the function of circSmoc1-2, one of the circRNAs generated from the *Smoc1* gene, which is downregulated in response to VC. CircSmoc1-2 is localized primarily to the cytoplasm and is resistant to exonuclease digestion. Inhibition of circSmoc1-2 worsens VC, while overexpression of circSmoc1-2 reduces VC, suggesting that circSmoc1-2 can prevent calcification. We went on to investigate the mechanism of circSmoc1-2 as a microRNA sponge and noted that miR-874-3p, the predicted target of circSmoc1-2, promotes VC, while overexpression of circSmoc1-2 reduces VC by suppressing miR-874-3p. Additionally, we identified the potential mRNA target of miR-874-3p as Adam19. In conclusion, we revealed that the circSmoc1-2/miR-874-3p/Adam19 axis regulates VC, suggesting that circSmoc1-2 may be a novel therapeutic target in the treatment of VC.

VC,³ the prevalence of VC continues to increase.^{4–6} Thus, it is necessary to investigate novel therapeutic targets for the treatment of patients with VC.

Recently, non-coding RNAs (ncRNAs) including microRNAs (miRNAs), long non-coding RNAs (lncRNA), and circular RNAs (circRNAs) have been reported to regulate diverse diseases.^{7–10} Most ncRNAs have low protein-coding potential, but they play important roles in various biological processes.⁷ However, although coding RNAs have been extensively evaluated, relatively little is known about the roles of ncRNAs. miRNAs are small ncRNAs with an average length of 23 nt that bind to the 3' untranslated region of messenger RNAs (mRNAs), inhibiting their translation and upregulating their degradation.⁷ lncRNAs are ncRNAs of more than 200 nt in length with a very diverse pool of functions, most of which are determined by their cellular localization. lncRNAs localized to the nucleus may directly regulate transcription, while lncRNAs localized in the cytoplasm can act as miRNA sponges.¹¹ CircRNAs are produced primarily by back-splicing when the 3' end of the downstream exon binds to the 5' end of the upstream exon, generating ncRNAs with a circular structure. Because circRNAs do not contain 5' or 3' ends, they are not easily digested by the exonucleases known to degrade linear RNAs.¹² CircRNAs can also act as miRNA sponges and

INTRODUCTION

Vascular calcification (VC) is the accumulation of calcium phosphate inside blood vessels. VC is known to be an independent risk factor of cardiovascular diseases (CVDs)¹ and results in vessel stiffness, which can ultimately lead to cardiac hypertrophy and ischemia.² Although several therapies used in patients with osteoporosis and chronic kidney disease (CKD) have been shown to be effective in the control of

Received 25 February 2021; accepted 20 December 2021;
<https://doi.org/10.1016/j.omtn.2021.12.031>.









Correspondence: Young-Kook Kim, Department of Biochemistry, Chonnam National University Medical School, Jeollanam-do, Republic of Korea.

E-mail: ykk@jnu.ac.kr

Correspondence: Hyun Kook, Department of Pharmacology, Chonnam National University Medical School, Jeollanam-do, Republic of Korea.

E-mail: kookhyun@jnu.ac.kr



A Generation of circSmoc1-2**B** Primer design for circSmoc1-2**C** Confirmation of circSmoc1-2 expression**D** Verification of circular form**E** Subcellular localization of circSmoc1-2

(legend on next page)

transcriptional or post-transcriptional regulators.^{13–15} Some circRNAs may interact with proteins¹⁵ or be involved in translation.^{16,17} Although various mechanisms of action have been reported for circRNAs, the molecular mechanism underlying their role as miRNA sponges is best understood,¹⁸ as this seems to be the major function of cytoplasmic circRNAs.¹⁹

Our research group has focused on evaluating the various regulatory functions of ncRNAs in VC. We previously reported several studies describing a number of ncRNAs involved in VC.²⁰ ncRNAs can function as both positive and negative regulators of VC.²¹ We recently reported that miR-134-5p induces VC by suppressing histone deacetylase 5,²² and miR-27a-3p targets *ATF3* to inhibit VC in vascular smooth muscle cells (VSMCs).²³ In addition, we found that the lncRNA *Lrrc75a-as1* works as a negative mediator of VC and inhibits osteoblast-related factors.²⁴ Moreover, we revealed that circ*Samd4a* has an anti-calcification effect and acts as a miRNA sponge, regulating *Camsap2* and *Flna*.²⁵ During this study of characterization of circRNAs in VC, we noticed that circ*Smoc1-2* was significantly downregulated following the induction of VC.²⁵ As the role of circ*Smoc1-2* has not been reported in any other studies, we decided to investigate the function and mechanism of this novel circRNA.

RESULTS

Characterization of circ*Smoc1-2* in vascular smooth muscle cells

We previously identified two VC-associated circRNAs generated from the *Smoc1* gene, circ*Smoc1-1* and circ*Smoc1-2*.²⁵ In the present study, we went on to evaluate the role of circ*Smoc1-2* as one of the circRNAs known to be downregulated in response to VC.²⁵ Circ*Smoc1-2* comprises four exons, namely, exons 4–7, of the *Smoc1* gene. The back-splicing junction for circ*Smoc1-2* was confirmed using Sanger sequencing, which is indicated by an arrow in Figure 1A. To confirm the differential expression of circ*Smoc1-2* under different conditions, we designed a set of divergent primers targeting the exons where back-splicing occurs (Figure 1B). Circ*Smoc1-2* was downregulated after the induction of VC (Figure 1C), as previously shown in RNA sequencing (RNA-seq) data.²⁵ To verify the circular structure, total RNA was treated with RNase R exonuclease. Circ*Smoc1-2* was shown to be resistant to RNase R digestion, while the *Smoc1* mRNA transcript was completely degraded (Figure 1D). We went on to investigate the subcellular localization of circ*Smoc1-2* and found that circ*Smoc1-2* resides mainly in the cytoplasm (Figure 1E).

Circ*Smoc1-2* inhibits VC

To conduct the functional study of circRNA, circ*Smoc1-2* was silenced using small interfering RNAs (siRNAs) (Figure 2A). As





circ*Smoc1-2* is found predominately in the cytoplasm (Figure 1E), where RNA interference-mediated gene silencing is effective, we designed two siRNAs to suppress circ*Smoc1-2* expression by binding to its splicing junction (Figure 2A). Circ*Smoc1-2* expression was markedly inhibited by these siRNAs, but there was no significant effect on *Smoc1* mRNA expression (Figure 2B). Expression of circ*Smoc1-2* was confirmed using the divergent primers, while *Smoc1* mRNA expression was verified using the convergent primers (Figure 2A). These siRNAs were then applied in the calcium assay, which revealed that inhibition of circ*Smoc1-2* increased calcium deposition (Figure 2C). The effect of silencing circ*Smoc1-2* was further confirmed using Alizarin red S (ARS) staining, which showed that calcium deposition increased in response to decreased circ*Smoc1-2* expression (Figure 2D). Given the results of calcium assay on the circ*Smoc1-2* inhibition, we went on to evaluate the effect of circ*Smoc1-2* overexpression. The circ*Smoc1-2* overexpression vector was created using a Laccase2 MCS Exon vector²⁶ backbone, which circularizes any inserted sequence. Transfection with this vector clearly upregulated circ*Smoc1-2* expression compared with the control (Figure 2E). Overexpression of circ*Smoc1-2* was confirmed using Sanger sequencing. The effects of this overexpression were then evaluated using the calcium assays and ARS staining assays. These assays revealed that the overexpression of circ*Smoc1-2* significantly reduces calcium deposition (Figures 2F and 2G). Taken together these results suggest that regulation of circ*Smoc1-2* affects VC.

Circ*Smoc1-2* acts as a sponge for miR-874-3p

As circ*Smoc1-2* is localized to the cytoplasm, we hypothesized that circ*Smoc1-2* may function as miRNA sponges. We used bioinformatics databases, miRDB,²⁷ and miRNA_targets²⁸ to produce a list of potential miRNA partners for circ*Smoc1-2*. Then we narrowed this list by evaluating the expression of these miRNAs in a microRNA microarray assay and identified those miRNAs exhibiting a negative correlation with circ*Smoc1-2* and significant differential expression in response to VC induction (see Materials and methods for more details) (Figure 3A). This analysis allowed us to identify miR-874-3p, which had a highly complement sequence in circ*Smoc1-2* at its seed region (Figure 3B). miR-874-3p was significantly upregulated following the induction of VC according to miRNA microarray (GEO: GSE130486)²³ (Figure 3C), and this expression profile was confirmed using quantitative real-time polymerase chain reaction (PCR) (Figure 3D). Furthermore, the regulatory relationship between circ*Smoc1-2* and miR-874-3p was evaluated using a calcium assay. The addition of a miR-874-3p mimic promoted calcium deposition, while circ*Smoc1-2* overexpression in the presence of the miR-874-3p mimic reduced calcium accumulation (Figures 3E and S1A). In addition, the inhibition of circ*Smoc1-2* induced calcium deposition,

Figure 1. Characterization of circ*Smoc1-2* in rat vascular smooth muscle cells (VSMCs)




(A) CircRNAs generated from *Smoc1*. (B) Construction of circ*Smoc1-2* primers around the splicing junction. Divergent primers were designed to detect circ*Smoc1-2* expression. (C) Verification of circ*Smoc1-2* expression following VC induction by RT-PCR ($n = 3$). Expression of circ*Smoc1-2* was normalized against Gapdh. Primary rat VSMCs were treated with 2 mM Pi for 6 h, 3 days, or 6 days. (D) Confirmation of circ*Smoc1-2* structure using RNase R digestion ($n = 3$). Linear RNA is degraded by RNase R, while circRNA is not. (E) Subcellular localization of circ*Smoc1-2* ($n = 3$). Pre-Gapdh and Gapdh were used as controls for the nuclear and cytoplasmic fractions, respectively. Data represent mean $\pm$ SEM. Statistical significance was determined using Student's *t* test (* $p \leq 0.05$, ** $p \leq 0.01$, and *** $p \leq 0.001$).

A siRNA and primer design**B** Confirmation of circSmoc1-2 knockdown**E** Confirmation of circSmoc1-2 overexpression**F** Measurement of Ca^{2+} amount

while the addition of a miR-874-3p inhibitor with a circSmoc1-2 siRNA reduced calcium deposition (Figure 3F). These results suggest that circSmoc1-2 functions as a miR-874-3p sponge during VC.

The circSmoc1-2/miR-874-3p/Adam19 axis regulates VC


As we were able to establish that circSmoc1-2 functions as a miR-874-3p sponge, we went on to identify the mRNA target of miR-874-3p. We first produced a list of potential mRNA targets using bioinformatics databases, namely, miRDB²⁷ and TargetScan,²⁸ and then narrowed

C Measurement of Ca^{2+} amount**D** Alizarin red S staining**G** Alizarin red S staining**Figure 2. Inhibitory role of circSmoc1-2 in vascular calcification (VC)**

(A) Construction of the siRNA and PCR primers. Two sets of siRNAs were designed against the splicing junction of circSmoc1-2. Divergent primers were then used to verify the expression of circSmoc1-2, while convergent primers were used to confirm the expression of Smoc1 mRNA. (B) Verification of circSmoc1-2 by knockdown using semi-quantitative RT-PCR ($n = 3$). CircSmoc1-2 and Smoc1 expression were both normalized against Gapdh. (C) Calcium concentration (mg Ca/mg protein) following circSmoc1-2 knockdown ($n = 3$). A10 cells were then treated with 2 mM inorganic phosphate (Pi) and cultured for an additional 3 days following transfection. (D) Alizarin red S (ARS) staining (mM) following circSmoc1-2 knockdown ($n = 3$). Representative images of ARS staining in each group are shown. The siCircSmoc1-2_1 was used to inhibit circSmoc1-2, and the cells were then treated with 4 mM Pi for an additional 3 days after transfection. (E) Validation of circSmoc1-2 overexpression ($n = 3$). The red asterisk denotes the endogenous circRNA band. Mock vector (MV) indicates the addition of the Laccase2 vector without an insert, while circSmoc1-2 refers to the circSmoc1-2 overexpression vector that includes a circSmoc1-2 sequence within the Laccase2 vector. (F) Calcium concentrations (mg Ca/mg protein) after circSmoc1-2 overexpression ($n = 3$). Cells were treated with 2 mM Pi for an additional 3 days following transfection. (G) ARS staining (mM) after circSmoc1-2 overexpression ($n = 3$). Transfected cells were also treated with 4 mM Pi and cultured for an additional 3 days prior to evaluation. Data represent mean $\pm$ SEM. Statistical significance was determined using Student's t test ($p \leq 0.05$, ** $p \leq 0.01$, and *** $p \leq 0.001$).

this list by evaluating RNA-seq data from the previous experiment.²⁵ This allowed us to narrow the list to mRNAs that negatively correlate with miR-874-3p expression and undergo a significant change following VC (see [Materials and methods](#) for more details) (Figure 4A). This analysis revealed several potential transcripts, but only Adam19 (a disintegrin and metalloproteinase domain 19) fulfilled all of the above selection criteria and included a miR-874-3p binding sequence (Figure 4B). RNA-seq data show that Adam19 is significantly downregulated following the induction of VC (Figure 4C),

and this expression pattern was confirmed using quantitative real-time PCR (Figure 4D). Next, we investigated whether miR-874-3p directly targets Adam19 in VSMCs using a quantitative real-time PCR and found that the addition of miR-874-3p significantly inhibited Adam19 expression (Figure 4E). In addition, the role of Adam19 in VC was examined using the calcium assay. Calcium deposition increased following the suppression of Adam19, while the overexpression of circSmoc1-2 reduced this effect (Figures 4F and S1B). Moreover, we also verified the protein level of Adam19, SMA (smooth





A Selection of target miRNA of circSmoc1-2miRNA target of circSmoc1-2
(miRDB, miRNA_targets) miRNA microarray after VC**Additional criteria**

- High average expression level
- Significant changes in expression after VC

B miRNA binding site within circSmoc1-2

```

mo-miR-874-3p 3' AGCCAGGGAGCCCGUCCCGUC 5'
                |||||:| |||||:|
circSmoc1-2    5' ACAAGCCUUGAGCCAGGGUAA 3'
113-134nt
  
```

C Expression change of miR-874-3p**D** Verification of miR-874-3p**E** Ca²⁺ amount with miR-874-3p mimic**F** Ca²⁺ amount with miR-874-3p inhibitor

muscle actin), Col1a1 (collagen type I alpha 1), and Alpl (alkaline phosphatase, tissue-nonspecific isozyme), which further supported results of mRNA level and calcium assay. The calcification marker Alpl was upregulated along with Col1a1 after the suppression of circSmoc1-2 in VSMCs with VC. On the contrary, the protein level of Adam19 and SMA were reduced after inhibition of circSmoc1-2 (Figure S2). The regulatory axis of circSmoc1-2/miR-874-3p/Adam19 was further validated in two *in vivo* VC models such as the CVD model with VC (Figure S1C) and vitamin D₃-administered mice model (Figure 5). Although the expression of circSmoc1-2 and Adam19 was reduced, expression of miR-874-3p was upregulated in these *in vivo* VC models (Figures 5 and S1C). Taken together these data reveal the circSmoc1-2/miR-874-3p/Adam19 axis, the novel regulatory axis that contributes to VC (Figure 6).

DISCUSSION

Although circRNAs have recently been evaluated in several diseases, there have been no previous reports describing the role of circSmoc1-2. This is the first study to evaluate the function of circSmoc1-2 in VC,

Figure 3. circSmoc1-2 acts as a microRNA (miRNA) sponge

(A) Schematic describing the identification of miRNA targets for circSmoc1-2. (B) miR-874-3p recognition sites within circSmoc1-2. (C) Expression of miR-874-3p as evaluated by miRNA microarray. Rat VSMC samples were collected at days 3 or 6 after Pi treatment, and miRNA microarrays were performed using these samples (GEO: GSE130486). (D) Verification of miR-874-3p expression using quantitative real-time PCR (n = 4). (E) Calcium concentrations (mg Ca/mg protein) after introducing miR-874-3p in A10 cells (n = 4). (F) Calcium concentration (mg Ca/mg protein) after adding an miR-874-3p inhibitor in A10 cells (n = 3). Cells were treated with 4 mM inorganic phosphate (Pi) and cultured for 2 days following each transfection. Data represent mean ± SEM. Statistical significance was determined using Student's t test (*p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001).

and our key finding is that circSmoc1-2 acts as a negative regulator of VC by functioning as a miR-874-3p sponge and indirectly regulating Adam19 (Figure 5).

CircSmoc1-2, a circRNA produced from the *Smoc1* gene (Figure 1A), is known to be down-regulated in response to VC (Figure 1C). It is RNase R resistant and localizes primarily to the cytoplasm (Figures 1D and 1E), demonstrating the general characteristics of most circRNAs.²⁹ Upregulation of circSmoc1-2 decreases calcium deposition (Figures 2F and 2G), suggesting that circSmoc1-2 plays an anti-calcification role in VC. As VC is

commonly found in patients with CKD or CVD, it is important to understand the underlying mechanisms regulating its severity and onset, as this may reveal a new therapeutic target. Because circSmoc1-2 regulates VC, it could be a novel target in the treatment of VC. Moreover, circSmoc1-2 is conserved in the human, mouse, and rat genomes (Figure S3A), and its expression in human coronary artery smooth muscle cells (HCASMCs) has been verified (Figure S3B). Thus, circSmoc1-2 could be studied in other animals and humans. Importantly, the function of the circSmoc1-2/miR-874-3p/Adam19 axis needs to be investigated in other cell types within vasculature and adverse effects of circSmoc1-2 should be tested before considering its clinical use as a diagnostic biomarker or therapeutic agent. In addition, circSmoc1-2 was found to be expressed in other cell types in liver, lung, and brain^{30,31} (Table S1). Therefore, the role of circSmoc1-2 in other organs can be further explored.

Because cytoplasmic circRNAs have been reported to function as miRNA sponges,^{13,32,33} we decided to investigate the potential action of circSmoc1-2 as a miRNA suppressor. We predicted that




Figure 4. miR-874-3p targets Adam19 during vascular calcification (VC)

(A) Schematic describing the identification of mRNA targets for miR-874-3p. (B) miR-874-3p/Adam19 binding sites. (C) The expression level of Adam19 in RNA-seq. (D) Verification of Adam19 expression using qualitative real-time PCR (n = 4). (E) Expression of Adam19 after adding a miR-874-3p mimic with or without Pi treatment. Cells were treated with 4 mM inorganic phosphate (Pi) for 2 days post-transfection. (F) Calcium concentration (mg Ca/mg protein) after Adam19 inhibition (n = 4). Cells were treated with 4 mM Pi and then cultured for an additional 2 days post-transfection. Data represent mean $\pm$ SEM. Statistical significance was determined using Student's t test (*p $\leq$ 0.05, **p $\leq$ 0.01, and ***p $\leq$ 0.001).

3p inhibited Adam19, verifying that miR-874-3p inhibits Adam19 expression in VC (Figure 4E). Finally, the relationship between circSmoc1-2 and Adam19 was evaluated using the calcium assay. Suppression of Adam19 increased VC, while overexpression of circSmoc1-2 reduced VC (Figure 4F). Thus, we identified that the circSmoc1-2/miR-874-3p/Adam19 axis is involved in VC pathogenesis (Figure 5). Previously, Adam19 has been studied in diverse diseases, such as congenital heart disease^{39,40} and cancer.^{41,42} Interestingly, miR-874-3p was reported to target Adam19 in nasopharyngeal carcinoma.⁴³ However, there have been no reports linking Adam19 to VC, suggesting that this is the first study to identify the value of Adam19 in VC pathogenesis.

miR-874-3p is a likely target of circSmoc1-2, as its expression increased following the induction of VC, demonstrating an inverse relationship with circSmoc1-2 expression. Their interaction was further supported by the presence of a complementary binding site in both RNA transcripts (Figure 3B), and circSmoc1-2 sequestration of miR-874-3p was confirmed using the VC model (Figures 3E and 3F). A miR-874-3p mimic induced VC, while circSmoc1-2 inhibited VC (Figure 3E). Likewise, inhibition of circSmoc1-2 promoted VC, while the addition of a miR-874-3p inhibitor suppressed VC (Figure 3F). Previously, miR-874-3p has been studied in various types of cancer,^{34–36} stroke,³⁷ and spinal degenerative disease.³⁸ However, the role of miR-874-3p in VC has not been established and this is the first study to show that miR-874-3p promotes VC.

We then went on to identify the target mRNA of miR-874-3p using bioinformatics databases and RNA-seq data²⁵ (Figure 4A). Adam19, which demonstrated a similar expression pattern to circSmoc1-2 and included miR-874-3p binding sites, was predicted as a target of miR-874-3p (Figures 4B–4D). Overexpression of miR-874-

Although our evaluations revealed that circSmoc1-2 acts as a miRNA sponge in VC, there may be other roles for this circRNA that should be evaluated in the future. As very few circRNAs have been reported to encode any kind of protein,¹⁶ the protein-coding potential of circSmoc1-2 was assessed using a bioinformatics database, circDb,⁴⁴ and was found to be low (Table S2); therefore, it is unlikely that circSmoc1-2 translates into any protein products. Our previous study also demonstrated that circRNA and its host gene, *Smoc1*, exhibit a positive correlation in their expression.²⁵ Therefore, further studies should be performed to assess circSmoc1-2 as a transcriptional regulator. In addition, several circRNAs were reported to interact with proteins or act as protein sponges.¹⁵ Thus, the potential of circSmoc1-2 interacting with proteins can be investigated.

ncRNAs have emerged as novel therapeutic targets for various diseases. They can regulate cellular pathways and modulate diverse diseases. Accumulating evidence suggests that RNA therapeutics can act as novel therapies in previously untreatable diseases.⁴⁵ Here, we revealed that circSmoc1-2 inhibits VC and functions as a miR-874-3p




Figure 5. Histological examination of circSmoc1-2, miR-874-3p, and Adam19 in mouse aorta with vitamin D₃-induced vascular calcification (VC) (A and B) Expression of (A) circSmoc1-2 and (B) miR-874-3p in mouse aortas with or without vitamin D₃ treatment for 6 days detected by *in situ* hybridization. circSmoc1-2 expression was identified using circSmoc1-2 probe specifically targeting the splicing junction of circSmoc1-2. Each red dot represents the single circSmoc1-2 transcript. Expression of circSmoc1-2 was downregulated in vitamin D₃-treated mouse aorta. miR-874-3p expression was detected using 5'-digoxigenin (DIG) and 3'-DIG-labeled miR-874-3p probe and shown as dark blue. miR-874-3p signals were upregulated in vitamin D₃-treated mouse aorta. (C and D) Expression of (C) Adam19 and (D) smooth muscle actin in mouse aortas with or without vitamin D₃ treatment for 6 days detected by fluorescent immunohistochemistry. Expression of Adam19 (red) and smooth muscle actin (green) was detected using anti-Adam19 antibody and anti-smooth muscle actin antibody, respectively. Expression of Adam19 and smooth muscle actin was downregulated in vitamin D₃-treated mouse aorta.

sponge modulating Adam19 expression. As there is no approved therapy for the treatment of VC, researchers should consider evaluating circSmoc1-2 as a novel therapeutic target for combating VC.

MATERIALS AND METHODS

Cell culture

VSMCs were isolated from 6-week-old male Sprague-Dawley rats and grown in 100 mm dishes (Eppendorf) with Dulbecco's modified ea-

gle's medium (DMEM) (LM001-05; Welgene) and 10% Hyclone fetal bovine serum (FBS) (GE Healthcare Life Sciences) up to passages 2–7. The rat VSMC cell line, A10 (CRL-1476; ATCC), was cultured in DMEM (LM001-05) with 10% FBS (Welgene). Human coronary artery smooth muscle cells (SMCs) were grown in medium 231 and SMC growth or differentiation supplement and were used at passages 4–8. The animal experiment was conducted following the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 8023, revised 1978). All animal experiment protocols were reviewed and approved by the Chonnam National University Medical School Research Institutional Animal Care and Use Committee.

Cellular models of VC and RNA isolation

The *in vitro* induction of VC was completed as previously described.²⁵ Primary rat VSMCs were treated with 2 mM inorganic phosphate (Pi) for 6 h, 3 days, or 6 days to induce VC. Total RNA from each of these four time points was then extracted using the TRIzol reagent (Thermo Fisher Scientific) as described in the manufacturer's instruction, and residual DNA was removed following DNase I (Takara) treatment.

RNase R treatment

We confirmed the circular structure of circSmoc1-2 using RNase R and 10× RNase R buffer (Epicentre). Although experimental samples were treated with RNase R, control samples were treated only with 10× RNase R buffer. The RNase R treatment was conducted at 37°C for 20 min and then inactivated at 95°C for 3 min.

Cell fractionation

Cell fractionation was completed using the protocol described in our previous publication.²⁵ In brief, A10 cells were washed twice with phosphate-buffered saline (PBS) and then removed from their 100 mm dish. The cells were pelleted and then resuspended in cool lysis buffer (20 mM HEPES, pH 7.4, 250 mM sucrose, 1 mM EDTA, 1 mM DTT) and then placed on ice for 25 min before adding 10% NP which was allowed to react for another 2 min on ice. These samples were then centrifuged at 2,000 × *g* and 4°C for 20 min, the cytoplasmic fraction was collected by centrifugation at 18,000 × *g* and 4°C for 20 min. The cell pellets containing the nuclear fraction were mixed with K100 buffer D (100 mM KCl, 20 mM Tris at pH 8.0, 0.2 mM EDTA) and centrifuged again at 10,000 rpm for 5 min at 4°C.

cDNA synthesis and PCR

Total RNA from A10 cells, HCASMCs, and mouse aortas from *ApoE* knockout (KO) mice was converted to cDNA and applied in the reverse transcriptase polymerase chain reaction (RT-PCR). Each RNA sample was mixed with 1 μL random hexamer (Thermo Fisher Scientific) and 1 μL RevertAid reverse transcriptase to produce cDNA and then used as a template in the semi-quantitative PCR to assess the expression levels of circRNA or mRNA. For miRNA cDNA synthesis, TaqMan Advanced miRNA assay (Applied Biosystems) or miScript II RT Kit (Qiagen) was used. Expression levels of circRNAs were evaluated using ImageJ (<http://imagej.nih.gov/ij/>)⁴⁶ and normalized




Figure 6. Schematic representation of the circSmoc1-2/miR-874-3p/Adam19 regulatory axis in vascular calcification (VC)

CircSmoc1-2 is a circRNA generated from the *Smoc1* locus via back-splicing. CircSmoc1-2 functions as an inhibitor of VC and acts as a miR-874-3p sponge regulating Adam19.

against Gapdh. Quantitative real-time PCR was used to evaluate the relative mRNA expression of various targets and was completed using a Power Sybr Green Master Mix (Applied Biosystems) or QuantiTect SYBR Green PCR kit (Qiagen) in a Rotor-Gene Q (Qiagen). The expression levels for the quantitative real-time PCR evaluations were normalized against 18S rRNA (4332641; Applied Biosystems), β -actin, or U6 (MS00033740; Qiagen) using the $2^{-\Delta C_t}$ method. Expression of miR-874-3p was detected using miR-874-3p primer purchased from Applied Biosystems or Qiagen. The primer sequences are summarized in Table S3.

circSmoc1-2 cloning

The full circSmoc1-2 sequence was cloned into a pcDNA3.1(+) Lacase2 MCS exon vector,²⁶ a gift from Jeremy Wilusz (Addgene plasmid #69893), to facilitate circSmoc1-2 overexpression. The primer sequences used to amplify circSmoc1-2 are provided in Table

S3. After cloning, the sequence of the circSmoc1-2 overexpression vector was verified using Sanger sequencing.

Design of siRNAs, miRNA mimics, and miRNA inhibitors

The small interfering RNAs against circSmoc1-2 were produced using two different tools, the siDesign center from Horizon Discovery (<https://horizondiscovery.com/design-center/>) and the i-Score designer (https://www.med.nagoya-u.ac.jp/neurogenetics/i_Score/i_score.html).⁴⁷ The siRNAs against circSmoc1-2 were designed to target the splicing junction, and siRNA against Adam19 mRNA for humans was constructed to base pair with exons within Adam19. These designed siRNAs were synthesized by Bioneer. The predesigned Adam19 siRNA for rat species, negative control siRNA, miR-874-3p mimic, and control miRNA were purchased from Bioneer. In addition, both the miR-874-3p inhibitor and negative miRNA inhibitor control were purchased from Qiagen.

Transfection

A total of 3.5×10^5 A10 cells were seeded in 60 mm dishes and used to evaluate circSmoc1-2 overexpression. Following seeding, 2.5 μ g of Lacase2 vector, with or without the circSmoc1-2 insert, was transfected into the A10 cells using Lipofectamine 3000 (Invitrogen). Additionally, 2×10^5 A10 cells were seeded for suppression of circSmoc1-2 in 60 mm dishes. After overnight incubation, these cells were transfected with 30 nM of each siRNA construct using Lipofectamine 3000. Negative control siRNAs were purchased from Bioneer, and the siRNA sequences are provided in Table S3. Furthermore, A10 cells were seeded in 60 mm dishes and transfected with 10 nM miR-874-3p mimic or control miRNA using Lipofectamine RNAiMAX after the cell reached 80% confluence to assess the expression change of Adam19 after 4 mM Pi treatment for 2 days.

Calcium assay

Calcium deposition was evaluated in A10 cells and HCASMCs grown in 24-well plates. When cells reached about 40% confluence, these cells were transfected with 0.25 μ g of the Lacase2 vector encoding circSmoc1-2 or 30 nM circSmoc1-2 siRNAs to evaluate the effects of circSmoc1-2 overexpression or inhibition, respectively. To assess the effect of miR-874-3p in VC, A10 cells and HCASMCs were grown in 24-well plates and then co-transfected with 30 nM miR-874-3p mimic and 0.25 μ g of the Lacase2 vector with circSmoc1-2. This was also validated by co-transfecting cells with 10 nM miR-874-3p inhibitor and 10 nM circSmoc1-2 siRNA in A10 cells. Additionally, to evaluate the role of Adam19 mRNA in VC, A10 cells and HCASMCs were grown in 24-well plates and then co-transfected with 30 nM Adam19 siRNA and 0.25 μ g of the Lacase2 vector expressing circSmoc1-2.

Following transfection, these cells were treated with 2–5 mM Pi for 1–3 days to induce VC. After the cells were washed with 1 $\times$ phosphate-buffered saline, cells were decalcified using 0.6 mol/L HCl incubated at 4°C for 1 day. These cells were then evaluated using a QuantiChrom calcium assay kit (BioAssay Systems), and the calcium concentration was normalized against the protein concentration for each experiment.

ARS staining and quantification

We verified the effects of both circSmoc1-2 knockdown and overexpression using A10 cells cultured in 24-well plates. Cells with 40% confluence were transfected with either 30 nM siRNA or 0.25 μ g overexpression vector. After 1 day, cells were treated with 4 mM Pi for 3 days. The cells were washed in PBS, fixed in 10% formalin for 1 h, washed three times with deionized water, and air-dried. These samples were then treated with 40 mM ARS solution (pH 4.2) (Sigma-Aldrich) and kept at 20°C–25°C. Then the ARS solution was removed, and samples were washed using PBS and deionized water. ARS staining was then quantified by dissolving the ARS precipitate in 10% cetylpyridinium chloride (Sigma-Aldrich) and evaluating the absorbance of this solution at 562 nm using a microplate spectrophotometer (BioTek).

miRNA predictions

Bioinformatics databases, including miRDB²⁷ and miRNA_targets,²⁸ were used to identify the miRNA targets of circSmoc1-2. The expression of these miRNAs was retrieved from bioinformatics databases cataloging miRNA microarray from rat VSMCs with Pi treatment for 3 or 6 days²³ (GEO: GSE130486). These target miRNA sequences were further filtered using the following criteria: average expression level ≥ 100 , 4-fold change on day 6 of Pi treatment, and miRNA seed region similarities. This evaluation identified miR-874-3p as the most likely target for circSmoc1-2.

mRNA prediction

mRNA targets of miR-874-3p were identified using several bioinformatics databases, including miRDB²⁷ and TargetScan.⁴⁸ The expression values for each of the potential target mRNAs were determined using the RNA-seq data from rat VSMCs following Pi treatment for 3 or 6 days.²⁵ These target mRNA candidates were then further validated using the following criteria: average expression level $\geq 1,000$, 4-fold change in expression on day 6 of Pi treatment, and a high degree of sequence similarity to the miRNA seed region. This selection process revealed that Adam19 shared a positive correlation with circSmoc1-2 and included a binding sequence for miR-874-3p, making this the obvious choice for our evaluations.

Western blot

Either negative control siRNA or circSmoc1-2 siRNA was transfected into A10 cells. On the next day, 2 mM Pi was added to cells for 3 days. Cells were treated with RIPA buffer (Translab) and were collected by scrapper. After protein quantification using the Pierce BCA Assay kit (Thermo Fisher Scientific), 13 μ g proteins were loaded into 8%–10% SDS-polyacrylamide gel and separated. Then proteins were transferred to polyvinylidene difluoride membrane (Millipore) after methanol activation. After blocking with 5% skim milk (BD Biosciences) and washing with 1 $\times$ TBS-T (Tris-buffered saline, 0.1% Tween 20) three times, membranes were incubated overnight at 4°C with primary antibodies. Primary antibodies were anti- α -tubulin antibody (11187-1-Ap; Proteintech), anti-Adam19 antibody (NBP1-69364; Novus Biologicals), anti-SMA antibody (sc-53015; Santa Cruz Biotechnology), anti- β tubulin antibody (sc-9935; Santa Cruz

Biotechnology) with a 1:1,000 dilution, and anti-collagen type I (ab34710, Abcam) with a 1:4,000 dilution. An anti-SMA antibody was used to detect α -SMA expression. Then membranes were washed three times with 1 $\times$ TBS-T and were incubated with secondary antibodies at room temperature (RT) for 1 h. Secondary antibodies were horseradish peroxidase-conjugated anti-rabbit, anti-mouse, or anti-goat immunoglobulin G antibody (Jackson ImmunoResearch). Finally, the membranes were treated with Immobilon Western Chemiluminescent HRP substrate (Millipore) and were detected using Fusion Solo (Vilber). For analysis of western blot image, ImageJ (<https://imagej.nih.gov/ij/>) was used, and β -tubulin was selected to normalize expression levels.

Animal model of vascular calcification

Vitamin D₃ was administered in mice to induce VC as described previously.²³ Vitamin D₃ in 70 μ L 100% ethanol was added to 500 μ L Cremophor (Alkamuls EL-620; Sigma-Aldrich) and incubated for 15 min at RT. Then the solution was transferred into 6.2 mL sterilized water including 250 mg dextrose and incubated for 15 min at RT. Finally, vitamin D₃ (150 μ L/25 g, 5×10^5 IU/kg/day) was administered subcutaneously for 3 days in 6- to 7-week-old C57BL/6 male mice, and mice were kept for 6 days. Age- and gender-matched vehicle mice received the solution prepared in the same manner without the inclusion of vitamin D₃ for the same period. After mice were sacrificed using intraperitoneal injection of 2,2,2-tribromoethanol (T48402; Sigma-Aldrich) at a dose of 240 mg/kg, the aorta was isolated and fixed in neutral buffered formalin at RT for 1 day and embedded in paraffin. Arterial sections (5 μ m) of vitamin D₃-administered mice were used for *in situ* hybridization and immunohistochemistry.

To induce atherosclerotic vascular calcification, 8-week-old *ApoE* knockout male mice were fed a high-fat and calcium-supplemented diet for 8 weeks. Simultaneously, age- and gender-matched *ApoE* knockout mice, vehicle group, were supplied with a normal chow diet for the same period. Then total RNA was isolated from the mice aorta using TRIzol reagent.

In situ hybridization

The expression of circSmoc1-2 was detected in arterial sections vehicle or vitamin D₃-administered mice using BaseScope Detection Reagent Kit v2-Red (323900; Advanced Cell Diagnostics [ACD]) as indicated in the manufacturer's protocol with slight modification. The circSmoc1-2 probe targeting splicing junctions of circSmoc1-2 was designed and synthesized from ACD. Briefly, slides were deparaffinized by xylene and ethanol and incubated with RNAscope hydrogen peroxide for 10 min at RT. After washing with deionized water three times, slides were immersed in RNAscope 1 $\times$ target retrieval reagents at 98°C for 15 min. Then slides were incubated with RNAscope protease IV at 40°C for 30 min in a HybEz oven and were hybridized with the circSmoc1-2 probe at 40°C overnight in a HybEz oven. Then signal of circSmoc1-2 was amplified with AMP 1-8 reagents. Finally, to detect the circSmoc1-2 chromogenic signal, slides were incubated with Basescope Fast RED for 10 min

and counterstained with Gill's hematoxylin and 0.02% ammonia water. After mounting the slides with VectaMount (Vector Laboratories), the images were visualized on the following day using an Axio scan.Z1 scanner (Carl Zeiss).

Expression of miR-874-3p was assessed in arterial sections of vehicle or vitamin D₃-treated mice using miR-874-3p miRCURY LNA miRNA detection probe (YD00616271-BEG; Qiagen) as described in the manufacturer's protocol with few modifications. Briefly, slides were deparaffinized using xylene and ethanol and incubated with Proteinase K for 10 min at 37°C. Then slides were washed with PBS-T two times and incubated with a hybridization mixture containing 5'-digoxigenin (DIG) and 3'-DIG-labeled 40 nM LNA miR-874-3p probe and miRNA ISH buffer at 55°C for overnight. After stringent washes with saline sodium citrate buffer, slides were incubated with blocking solution for 15 min at RT in a humidified chamber. Then slides were incubated with an anti-DIG antibody (1:800) for 1 h at RT. Then slides were washed with PBS-T three times and incubated with AP substrate at 30°C overnight. After counterstaining with Nuclear Fast Red for 1 min, slides were mounted and observed on the next day using an Axio scan.Z1 scanner (Carl Zeiss).

Immunohistochemistry

Protein expression in aortic sections of vitamin D₃-administered mice was assessed using fluorescent immunohistochemistry as previously described²³ using anti-Adam19 antibody (NBP1-69364; Novus Biologicals) and anti-smooth muscle actin antibody (sc-53015; Santa Cruz Biotechnology) with a 1:100 dilution. The photographs of aortic sections were visualized using a Zeiss LSM 710 confocal microscope (Carl Zeiss).

Statistical analysis

Data are shown as mean $\pm$ standard error of the mean (SEM). Statistical significance was determined using Student's t test, and differences with p values $\leq$ 0.05 were considered statistically significant.

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.omtn.2021.12.031>.

ACKNOWLEDGMENTS

We would like to take this opportunity to convey our gratitude to all of our colleagues from the Departments of Pharmacology and Biochemistry at Chonnam National University Medical School who made significant contributions to this research. This study was supported by grants from the Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Science, ICT & Future Planning (NRF-2021R1A2B5B02001501, NRF-2018R1A2B3001503, NRF-2019R1A4A1028534, NRF-2021R1C1C2009289). The funders played no role in designing this study, collecting or analyzing the data, or preparing or publishing the manuscript. The graphical abstract and Figure 6 was created using BioRender.com

AUTHOR CONTRIBUTIONS

J.R., H.K., and Y.-K.K. designed the study. J.R., N.C., D.-H.K., S.S., Y.-H.L., G.Y., and J.H.K. conducted the experiments. J.R. collected the data. J.R., H.K., Y.-K.K. analyzed and interpreted the data. J.R. wrote the first draft. J.R., H.S.K., I.-K.L., Y.A., W.J.P., H.K., and Y.-K.K. revised the manuscript. J.R., H.K., and Y.-K.K. acquired funding.

DECLARATION OF INTERESTS

There authors declare no competing interests.

REFERENCES

1. Sage, A.P., Tintut, Y., and Demer, L.L. (2010). Regulatory mechanisms in vascular calcification. *Nat. Rev. Cardiol.* 7, 528–536.
2. Mizobuchi, M., Towler, D., and Slatopolsky, E. (2009). Vascular calcification: the killer of patients with chronic kidney disease. *J. Am. Soc. Nephrol.* 20, 1453–1464.
3. Wu, M., Rementer, C., and Giachelli, C.M. (2013). Vascular calcification: an update on mechanisms and challenges in treatment. *Calcified Tissue Int.* 93, 365–373.
4. Kraus, M.A., Kalra, P.A., Hunter, J., Menoyo, J., and Stankus, N. (2015). The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: a cross-sectional observational study. *Ther. Adv. Chronic Dis.* 6, 84–96.
5. Niu, Q., Zhao, H., Wu, B., Tsai, S., Wu, J., Zhang, M., Lu, L., Qiao, J., Men, C., Zuo, L., et al. (2019). Study on the prevalence of vascular calcification in different types of arteries and influencing factors in maintenance peritoneal dialysis patients. *Blood Purif.* 47, 8–16.
6. Wang, X.-R., Zhang, J.-J., Xu, X.-X., and Wu, Y.-G. (2019). Prevalence of coronary artery calcification and its association with mortality, cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis. *Ren. Fail.* 41, 244–256.
7. Esteller, M. (2011). Non-coding RNAs in human disease. *Nat. Rev. Genet.* 12, 861–874.
8. Boeckel, J.N., Jae, N., Heumuller, A.W., Chen, W., Boon, R.A., Stellos, K., Zeiher, A.M., John, D., Uchida, S., and Dimmeler, S. (2015). Identification and characterization of hypoxia-regulated endothelial circular RNA. *Circ. Res.* 117, 884–890.
9. Gruner, H., Cortes-Lopez, M., Cooper, D.A., Bauer, M., and Miura, P. (2016). CircRNA accumulation in the aging mouse brain. *Scientific Rep.* 6, 38907.
10. Lim, Y.H., Ryu, J., Kook, H., and Kim, Y.K. (2020). Identification of long noncoding RNAs involved in differentiation and survival of vascular smooth muscle cells. *Mol. Ther. Nucleic Acids* 22, 209–221.
11. Fatica, A., and Bozzoni, I. (2014). Long non-coding RNAs: new players in cell differentiation and development. *Nat. Rev. Genet.* 15, 7–21.
12. Lasda, E., and Parker, R. (2014). Circular RNAs: diversity of form and function. *RNA* 20, 1829–1842.
13. Hansen, T.B., Jensen, T.I., Clausen, B.H., Bramsen, J.B., Finsen, B., Damgaard, C.K., and Kjems, J. (2013). Natural RNA circles function as efficient microRNA sponges. *Nature* 495, 384–388.
14. Peng, L., Yuan, X.Q., and Li, G.C. (2015). The emerging landscape of circular RNA ciRS-7 in cancer (Review). *Oncol. Rep.* 33, 2669–2674.
15. Qu, S., Zhong, Y., Shang, R., Zhang, X., Song, W., Kjems, J., and Li, H. (2017). The emerging landscape of circular RNA in life processes. *RNA Biol.* 14, 992–999.
16. Legnini, I., Di Timoteo, G., Rossi, F., Morlando, M., Briganti, F., Sthandier, O., Fatica, A., Santini, T., Andronache, A., Wade, M., et al. (2017). Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis. *Mol. Cell* 66, 22–37.e9.
17. Pamudurti, N.R., Bartok, O., Jens, M., Ashwal-Fluss, R., Stottmeister, C., Ruhe, L., Hanan, M., Wyler, E., Perez-Hernandez, D., Ramberger, E., et al. (2017). Translation of CircRNAs. *Mol. Cell* 66, 9–21.e7.
18. Zhao, X., Cai, Y., and Xu, J. (2019). Circular RNAs: biogenesis, mechanism, and function in human cancers. *Int. J. Mol. Sci.* 20, 3926.
19. Shang, Q., Yang, Z., Jia, R., and Ge, S. (2019). The novel roles of circRNAs in human cancer. *Mol. Cancer* 18, 6.

20. Ryu, J., Ahn, Y., Kook, H., and Kim, Y.K. (2021). The roles of non-coding RNAs in vascular calcification and opportunities as therapeutic targets. *Pharmacol. Ther.* 218, 107675.
21. Kwon, D.H., Ryu, J., Kim, Y.K., and Kook, H. (2020). Roles of histone acetylation modifiers and other epigenetic regulators in vascular calcification. *Int. J. Mol. Sci.* 21, 3246.
22. Choe, N., Shin, S., Joung, H., Ryu, J., Kim, Y.K., Ahn, Y., Kook, H., and Kwon, D.H. (2020). The microRNA miR-134-5p induces calcium deposition by inhibiting histone deacetylase 5 in vascular smooth muscle cells. *J. Cell Mol. Med.* 24, 10542–10550.
23. Choe, N., Kwon, D.H., Ryu, J., Shin, S., Cho, H.J., Joung, H., Eom, G.H., Ahn, Y., Park, W.J., Nam, K.I., et al. (2020). miR-27a-3p targets ATF3 to reduce calcium deposition in vascular smooth muscle cells. *Mol. Ther. Nucleic Acids* 22, 627–639.
24. Jeong, G., Kwon, D.H., Shin, S., Choe, N., Ryu, J., Lim, Y.H., Kim, J., Park, W.J., Kook, H., and Kim, Y.K. (2019). Long noncoding RNAs in vascular smooth muscle cells regulate vascular calcification. *Sci. Rep.* 9, 5848.
25. Ryu, J., Kwon, D.H., Choe, N., Shin, S., Jeong, G., Lim, Y.H., Kim, J., Park, W.J., Kook, H., and Kim, Y.K. (2020). Characterization of circular RNAs in vascular smooth muscle cells with vascular calcification. *Mol. Ther. Nucleic Acids* 19, 31–41.
26. Kramer, M.C., Liang, D., Tatomer, D.C., Gold, B., March, Z.M., Cherry, S., and Wilusz, J.E. (2015). Combinatorial control of *Drosophila* circular RNA expression by intronic repeats, hnRNPs, and SR proteins. *Genes Dev.* 29, 2168–2182.
27. Wong, N., and Wang, X. (2015). miRDB: an online resource for microRNA target prediction and functional annotations. *Nucleic Acids Res.* 43, D146–D152.
28. Kumar, A., Wong, A.K.L., Tizard, M.L., Moore, R.J., and Lefèvre, C. (2012). miRNA_Targets: a database for miRNA target predictions in coding and non-coding regions of mRNAs. *Genomics* 100, 352–356.
29. Liu, L., Wang, J., Khanabadi, R., Kalonis, B., Tai, X., and Xia, S. (2017). Circular RNAs: isolation, characterization and their potential role in diseases. *RNA Biol.* 14, 1715–1721.
30. Salzman, J., Chen, R.E., Olsen, M.N., Wang, P.L., and Brown, P.O. (2013). Cell-type specific features of circular RNA expression. *Plos Genet.* 9, e1003777.
31. Rybak-Wolf, A., Stottmeister, C., Glazar, P., Jens, M., Pino, N., Giusti, S., Hanan, M., Behm, M., Bartok, O., Ashwal-Fluss, R., et al. (2015). Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. *Mol. Cell* 58, 870–885.
32. Kulcheski, F.R., Christoff, A.P., and Margis, R. (2016). Circular RNAs are miRNA sponges and can be used as a new class of biomarker. *J. Biotechnol.* 238, 42–51.
33. Cheng, D., Wang, J., Dong, Z., and Li, X. (2021). Cancer-related circular RNA: diverse biological functions. *Cancer Cell Int.* 21, 11.
34. Xia, B., Lin, M., Dong, W., Chen, H., Li, B., Zhang, X., Hou, Y., and Lou, G. (2018). Upregulation of miR-874-3p and miR-874-5p inhibits epithelial ovarian cancer malignancy via SIK2. *J. Biochem. Mol. Toxicol.* 32, e22168.
35. Liu, W.G., Zhuo, L., Lu, Y., Wang, L., Ji, Y.X., and Guo, Q. (2020). miR-874-3p inhibits cell migration through targeting RGS4 in osteosarcoma. *J. Gene Med.* 22, e3213.
36. Yuan, R.B., Zhang, S.H., He, Y., Zhang, X.Y., and Zhang, Y.B. (2018). MiR-874-3p is an independent prognostic factor and functions as an anti-oncomir in esophageal squamous cell carcinoma via targeting STAT3. *Eur. Rev. Med. Pharmacol. Sci.* 22, 7265–7273.
37. Xie, K., Cai, Y., Yang, P., Du, F., and Wu, K. (2020). Upregulating microRNA-874-3p inhibits CXCL12 expression to promote angiogenesis and suppress inflammatory response in ischemic stroke. *Am. J. Physiol. Cell Physiol.* 319, C579–C588.
38. Song, Q., Zhang, F., Wang, K., Chen, Z., Li, Q., Liu, Z., and Shen, H. (2021). MiR-874-3p plays a protective role in intervertebral disc degeneration by suppressing MMP2 and MMP3. *Eur. J. Pharmacol.* 895, 173891.
39. Arai, H.N., Sato, F., Yamamoto, T., Woltjen, K., Kiyonari, H., Yoshimoto, Y., Shukunami, C., Akiyama, H., Kist, R., and Sehara-Fujisawa, A. (2019). Metalloprotease-dependent attenuation of BMP signaling restricts cardiac neural crest cell fate. *Cell Rep.* 29, 603–616.e5.
40. Zhou, H.M., Weskamp, G., Chesneau, V., Sahin, U., Vortkamp, A., Horiuchi, K., Chiusaroli, R., Hahn, R., Wilkes, D., Fisher, P., et al. (2004). Essential role for ADAM19 in cardiovascular morphogenesis. *Mol. Cell Biol.* 24, 96–104.
41. Hoyne, G., Rudnicka, C., Sang, Q.X., Roycik, M., Howarth, S., Leedman, P., Schlaich, M., Candy, P., and Matthews, V. (2016). Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer. *BMC Cancer* 16, 151.
42. Wang, Y., Lian, Y.M., and Ge, C.Y. (2019). MiR-145 changes sensitivity of non-small cell lung cancer to gefitinib through targeting ADAM19. *Eur. Rev. Med. Pharmacol. Sci.* 23, 5831–5839.
43. Feng, X., Xue, H., Guo, S., Chen, Y., Zhang, X., and Tang, X. (2019). MiR-874-3p suppresses cell proliferation and invasion by targeting ADAM19 in nasopharyngeal carcinoma. *Panminerva Med.* 63, 238–239.
44. Chen, X., Han, P., Zhou, T., Guo, X., Song, X., and Li, Y. (2016). circRNADb: a comprehensive database for human circular RNAs with protein-coding annotations. *Scientific Rep.* 6, 34985.
45. Kim, Y.K. (2020). RNA therapy: current status and future potential. *Chonnam Med. J.* 56, 87–93.
46. Schneider, C.A., Rasband, W.S., and Eliceiri, K.W. (2012). NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods* 9, 671–675.
47. Ichihara, M., Murakumo, Y., Masuda, A., Matsuura, T., Asai, N., Jijiwa, M., Ishida, M., Shinmi, J., Yatsuya, H., Qiao, S., et al. (2007). Thermodynamic instability of siRNA duplex is a prerequisite for dependable prediction of siRNA activities. *Nucleic Acids Res.* 35, e123.
48. Lewis, B.P., Burge, C.B., and Bartel, D.P. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 120, 15–20.